Drug Alerts and Special Reports

The BuyandBill.com newsletter provides important information pertaining to key reimbursement related events for new and existing office-administered products. Our newsletter is sent from BuyandBill.com on behalf of pharma manufacturers. The newsletter includes the following information: C-Code alerts, J-code alerts, NCCN alerts, New NDC alerts, Updates on Pricing information, and more. Click here to opt in to our newsletter.

Permanent J-Code for RYSTIGGO® (rozanolixizumab-noli): Available January 1, 2024 – 11/30/23

VABYSMO® (faricimab-svoa): New Indication Now Approved – 11/6/23

Samsung Bioepis Biosimilar Market Report 3rd Edition, Q4 2023 – 10/10/23

Setmelanotide as a Protein replacement agent: USP Medicare Modeling Guidelines – 10/5/23

Now Approved: VANFLYTA® (quizartinib) for FLT3-ITD AML – 10/3/23

Now Approved: The Latest Treatment For Some Adults With Late-Onset Pompe Disease – 10/02/23

Permanent J-Code for ZYNYZ™ (retifanlimab-dlwr): Available October 1st, 2023

Important Price Change Announcement for Photrexa® – 9/28/23

Permanent J-Code for REZZAYO™ (rezafungin for injection): Effective October 1, 2023 – 9/19/23

New Indication for Bardet-Biedl syndrome (BBS) – 9/15/23

Safely Treating Molluscum Using YCANTH (FDA) – 9/13/23

Now Approved: APHEXDA™ (motixafortide) for injection – 9/12/2023